Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

A single interactive map for all that is known on COVID-19


Dr. Anna Niarakis, teaching researcher in bioinformatics and computational systems biology at the Genopole laboratory GenHotel (University of Évry) is one of the four coordinators for the international COVID-19 Disease Map project.
COVID-19 Disease Map >
Covid-19 D Covid-19 D

Responding to a call made by the Disease Maps community, close to 200 scientists from 100 institutions in 24 countries are participating in the project.
The objective for this latter is to build a sole referential comprising the totality of scientific knowledge on SARS-CoV-2/human-host interactions and thus contribute to the identification of therapeutic possibilities.

This major collaborative project has resulted in a platform that is available to the entire scientific community and constantly evolving as knowledge on COVID-19 advances. Presented in the form of an interactive map, the platform compiles all available data on virus/human-host molecular interactions and their roles in the complex mechanisms of the disease: infection processes, biological pathways and affected cells, viral proliferation, inflammatory responses, etc. In this way, the contributors to the project hope to more effectively increase our understanding of COVID-19 and accelerate the development of diagnostics and therapeutics.

As the project’s modeling coordinator, Anna Niarakis will deploy the dynamic modeling tool she developed at Inria within the GenHotel laboratory originally for rheumatoid arthritis. That tool enables virtual testing of the effects of perturbations on disease course, particularly viral proliferation, cellular death and inflammation. By crossing such analyses with therapeutics databases, it becomes possible to identify drug candidates.

Logo - Covid-19 Disease Map

COVID-19 Disease Map

The COVID-19 Disease Map enables visual explorations and computational analyses of the molecular mechanisms involved in SARS-CoV-2 viral entry and multiplication, virus/host interactions, immune responses and cell recuperation. The main challenge it faces is to associate rapidity and reliability in the race against the unprecedented COVID-19 pandemic. This includes not only the exhaustive collection of data, but also the verification of the reliability of those data, which are often taken from increasingly present preprint articles. Bioinformaticians organize and explore those highly informative data then biologists, virologists and clinicians verify models.

COVID-19 Disease Map: providing all competencies

The active participation of close to 200 scientists provides all the competencies needed for a better understanding of COVID-19:

  • the molecular and clinical aspects of the pathology;
  • molecular interaction characterizations and systems biology schemas illustrating disease mechanisms;
  • medical literature reviews;
  • the integration of diverse databases and bioinformatics expertise;
  • computational modeling to analyze disease-associated perturbations via systems biology approaches.

The initiative: mutualize expertise and energy to meet the challenges of COVID-19

The COVID-19 Disease Map project is an interdisciplinary effort involving researchers and clinicians with complementary competencies to rise to the challenge of COVID-19. It benefits from the participation of renowned international scientific groups that strengthen the project in a wide range of domains. The various project orientations progress together thanks to the volunteer work and enthusiasm of the project’s community.

The international scientific community’s massive participation in the project stands as a positive signal for the future, wherein all can indeed come together for a shared cause, achieve concrete results and accelerate the fight against a sinister disease.

The GenHotel lab actively engaged in the battle

Four people are in charge of managing and advancing the COVID-19 Disease Map project: Dr. Marek Ostaszewski (University of Luxembourg), Dr. Alexander Mazein (University of Luxembourg), Dr. Inna Kuperstein (Institut Curie) and Dr. Anna Niarakis (University of Évry, Paris-Saclay University).

Dr. Anna Niarakis is an associate professor at the University of Évry–Paris-Saclay and a researcher at GenHotel, the Genopole laboratory for complex diseases and rheumatoid arthritis. From day one of the project, she has been actively involved in several axes:

  • project conception and management;
  • map construction;
  • development of data analysis pipelines and dynamic modeling.

She has teamed with Vidisha Singh, PhD student at GenHotel and Sara Sadat Aghamiri, Inserm engineer at the Saint-Louis Hospital and GenHotel to construct graphs of disease-associated biological mechanisms using SBGN (Systems Biology Graphical Notation Scheme) notation and MIRIAM (Minimum Information Required in the Annotation) identifiers.
Their team deploys competencies to construct large-scale molecular maps, including the recently-published rheumatoid arthritis map. (show map).

Dr. Niarakis also coordinates bioinformatics analysis and computational modelling for the COVID-19 Disease Map project. A program called CasQ, which she developed with Sylvain Soliman of INRIA-Saclay’s Lifeware team and recently published in Bioinformatics (read the article), is used in that setting to produce discrete models executable at a large scale from molecular maps.

The COVID-19 Disease Map objectives in brief:

The COVID-19 molecular map will:

  1. serve as a high-quality, complete, easily-accessed resource with human curation;
  2. provide integrated solutions for textual exploration and artificial-intelligence assisted data exploration for improved content conservation and enrichment;
  3. ensure free access to reusable and interoperable content that interfaces with other databases and data referentials;
  4. provide a multi-omic data analysis platform with assisting disease maps, drug repurposing information and clinical data integration systems;
  5. furnish a mechanistic model for the development of computer models for in silico simulations of combined perturbations (KO, KI) and predictions of novel therapeutic targets;
  6. act as a community hub enabling the development of state of the art technologies for tomorrow’s medical challenges.

To learn more about the COVID-19 Disease Map project

Click here if you would like to contribute to the project

Article posted on 5 May 2020

Share
Highlights

The latest news


Neurons representation - Cells affected by CMT

Gene therapy for Charcot-Marie-Tooth disease makes headway

A gene therapy for Charcot-Marie-Tooth disease has been shown to be efficacious in an animal-model study cosigned by a research team created through Genopole support.

Discover
LAST - Makeup by Global Bioenergies

Global Bioenergies launches its makeup brand

Interview with Marc Delcourt, founder and CEO of Global Bioenergies, launches its makeup brand : LAST

Discover
NEB France celebrate 10 years @ Genopole

New England Biolabs France Celebrates 10 Years!

Its French affiliate arrived at Genopole in 2011 and to mark its 10th anniversary in France, the company invites you to participate in monthly activities to be held throughout 2021.

Discover
Visualization and quantification by MTBench technology of protein-protein interactions observed at Opera Phenix + in a cell line.

Seeing in high resolution at the Structural Biology Platform

With the support of Genopole & the University of Évry and to enrich its technological offer, the Structural Biology Platform has acquired the Opera Phenix Plus high content screening (HCS) system.

Discover
MSCA COFUND 2020 - ApogeeBio Laureate

COFUND-MSCA2020 : ApogeeBio chosen by the EC

Submitted by Genopole and its on-site partners, the ApogeeBio project for research grants has been selected by the European Commission for Marie Skłodowska-Curie Actions co-funding (MSCA-Cofund-2020).

Discover
Genhotel -  fibroblastes, cancer & Polyarthrite

Metabolic reprogramming involved in rheumatoid arthritis and cancer

The researchers from GenHotel (University of Évry-Paris Saclay, Genopole) have shed light on certain aspects common to rheumatoid arthritis and cancer.

Discover
AB Science L. Gros

Multiple sclerosis and COVID-19: promising results from AB Science

AB Science has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis.

Discover
Placton - Tara Oceans

Bioinformatics and Tara Oceans

A team from the Genomics Metabolics Laboratory (Genoscope – CEA/CNRS/University of Évry) has developed a bioinformatics method for environmental genomics analyses able to identify species and associations of species.

Discover
Globules rouges - Avancées scientifiques

CRISPR-Cas9 for blood and metabolic diseases – Integrare

In an article published in Nature Communications, an Integrare team headed by Dr. Mario Amendola has described an innovative genome editing strategy aimed at modifying hematopoietic stem cells.

Discover
Généthon - Genopole's Laboratory

Treating more patients with gene therapies – Généthon

A Genethon team has successfully inhibited immune response to adeno-associated virus vectors, and in so doing, opened potential paths for treating more patients with gene therapies.

Discover
cellular membrane

Mapping membrane nanotubes – Lambe

A team from the Genopole-accredited Laboratory for Analysis and Modeling in Biology and the Environment (Lambe) has developed an experimental technique to study cell membrane nanotubes. These largely unknown structures play an essential role in cellular biomolecule transport.

Discover
Laboratory

Toward the industrialization of gene therapies -Polytheragene

Polytheragene is developing a polymer that will improve upon the current market standards for the production of viral particles for therapeutics. The polymer will be used by Genethon and Yposkesi to enhance the bioproduction of gene therapy vectors.

Discover
Jean Weissenbach

Jean Weissenbach: a portrait

Jean Weissenbach, a pioneer in France for the exploration of the human genome and a scientific icon at Genopole, talks about his career in an interview published 18 March 2020 in CNRS News.

Discover
cellular membrane

A nanopore to identify amino acids – Lambe

A team from the Laboratory for Analysis and Modeling in Biology and the Environment (Lambe – University of Évry/University of Cergy-Pontoise/CNRS) used a natural aerolysin nanopore to successfully identify 13 of the 20 amino acids that make up proteins.

Discover
Genopole - European projects

Green light from Europe for the Genopole-coordinated project GEN.ERA

Le projet européen GEN.ERA*, coordonné par Genopole, est sélectionné par la Commission européenne. Il vise à renforcer par une coopération entre clusters, l’internationalisation d’entreprises du secteur de la génomique au-delà du continent européen.

Discover
actus

New accomplishment in gene therapies

A clinical trial for a gene therapy to treat a severe immunodeficiency has provided highly promising initial results.

Discover
View all >
With support